Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Animals
Apoptosis
Breast Neoplasms
/ drug therapy
Cell Proliferation
Cyclin-Dependent Kinase 8
/ antagonists & inhibitors
Cyclin-Dependent Kinases
/ antagonists & inhibitors
Cytotoxicity, Immunologic
/ immunology
Female
Humans
Killer Cells, Natural
/ drug effects
Leukemia, Myeloid, Acute
/ drug therapy
Melanoma, Experimental
/ drug therapy
Mice
Mice, Inbred C57BL
Mice, Inbred NOD
Mice, SCID
Phosphorylation
Protein Kinase Inhibitors
/ pharmacology
STAT1 Transcription Factor
/ metabolism
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
12
08
2019
revised:
18
12
2019
accepted:
28
01
2020
pubmed:
7
2
2020
medline:
7
4
2021
entrez:
7
2
2020
Statut:
ppublish
Résumé
Natural killer (NK) cells play a pivotal role in controlling cancer. Multiple extracellular receptors and internal signaling nodes tightly regulate NK activation. Cyclin-dependent kinases of the mediator complex (CDK8 and CDK19) were described as a signaling intermediates in NK cells. Here, we report for the first time the development and use of CDK8/19 inhibitors to suppress phosphorylation of STAT1
Identifiants
pubmed: 32024684
pii: 1535-7163.MCT-19-0789
doi: 10.1158/1535-7163.MCT-19-0789
pmc: PMC7661742
mid: NIHMS1556854
doi:
Substances chimiques
Protein Kinase Inhibitors
0
STAT1 Transcription Factor
0
STAT1 protein, human
0
CDK19 protein, human
EC 2.7.11.22
CDK8 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 8
EC 2.7.11.22
Cyclin-Dependent Kinases
EC 2.7.11.22
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1018-1030Subventions
Organisme : NCI NIH HHS
ID : F99 CA245813
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA159296
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197844
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
J Med Chem. 2016 Feb 11;59(3):1078-101
pubmed: 26796641
Nat Chem Biol. 2015 Dec;11(12):973-980
pubmed: 26502155
Nature. 2015 Oct 8;526(7572):273-276
pubmed: 26416749
Proc Natl Acad Sci U S A. 2013 May 14;110(20):8081-6
pubmed: 23630251
Biochim Biophys Acta. 2015 Oct;1854(10 Pt B):1617-29
pubmed: 26006748
Nature. 2008 Sep 25;455(7212):547-51
pubmed: 18794900
Cancer Cell. 2018 Apr 9;33(4):581-598
pubmed: 29634946
Leukemia. 2017 Oct;31(10):2172-2180
pubmed: 28096534
J Immunol. 2000 Oct 1;165(7):3571-7
pubmed: 11034357
Blood. 2016 Jun 9;127(23):2879-89
pubmed: 27013443
Semin Immunol. 2014 Apr;26(2):138-44
pubmed: 24629893
Lancet. 2000 Nov 25;356(9244):1795-9
pubmed: 11117911
J Clin Invest. 2018 Oct 1;128(10):4654-4668
pubmed: 30198904
J Clin Oncol. 2009 Mar 1;27(7):1122-9
pubmed: 19164213
Nat Commun. 2014 Oct 30;5:5108
pubmed: 25355530
Nat Rev Drug Discov. 2015 Jul;14(7):487-98
pubmed: 26000725
Oncotarget. 2017 May 16;8(20):33779-33795
pubmed: 28422713
Apoptosis. 2017 Jul;22(7):898-919
pubmed: 28424988
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
J Immunol. 1987 Jun 15;138(12):4539-44
pubmed: 3584981
Haematologica. 2015 May;100(5):643-52
pubmed: 25682594
Oncotarget. 2017 Feb 21;8(8):12558-12575
pubmed: 28147342
J Clin Invest. 2018 Aug 1;128(8):3209-3218
pubmed: 30067248
Leuk Lymphoma. 2014 Mar;55(3):645-51
pubmed: 23697877
Oncoimmunology. 2014 Apr 29;3:e28541
pubmed: 25050221
Immunol Rev. 2006 Dec;214:73-91
pubmed: 17100877
Int J Cancer. 2004 Mar;109(1):85-94
pubmed: 14735472
Genes Cells. 2011 Dec;16(12):1208-18
pubmed: 22117896
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Oncoimmunology. 2016 May 19;5(9):e1186314
pubmed: 27757297
J Med Chem. 2018 Jun 28;61(12):5073-5092
pubmed: 29266937
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Cell Rep. 2013 Aug 15;4(3):437-44
pubmed: 23933255
Int J Clin Lab Res. 1997;27(1):48-54
pubmed: 9144027
J Clin Oncol. 2008 Apr 10;26(11):1789-96
pubmed: 18347005
Blood. 2008 Aug 1;112(3):461-9
pubmed: 18650461
Elife. 2016 Dec 09;5:
pubmed: 27935476
Adv Immunol. 2009;101:27-79
pubmed: 19231592
Oncotarget. 2018 Jan 3;9(11):9706-9713
pubmed: 29515764
Cancer Immunol Res. 2018 Apr;6(4):458-466
pubmed: 29386186
J Pharmacol Exp Ther. 2015 Mar;352(3):579-89
pubmed: 25576074
Immunity. 2013 Feb 21;38(2):250-62
pubmed: 23352233
Nat Commun. 2017 Feb 15;8:
pubmed: 28198370
Trends Immunol. 2009 Apr;30(4):143-9
pubmed: 19282243
Clin Cancer Res. 2015 Sep 15;21(18):4055-61
pubmed: 25999435
J Biomol Screen. 2011 Mar;16(3):370-7
pubmed: 21335598
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13799-804
pubmed: 22869755
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Cancer Immunol Res. 2018 Jan;6(1):25-35
pubmed: 29187357